NO20042876L - Farmasoytisk blanding for regenerering av cirrhotisk lever - Google Patents

Farmasoytisk blanding for regenerering av cirrhotisk lever

Info

Publication number
NO20042876L
NO20042876L NO20042876A NO20042876A NO20042876L NO 20042876 L NO20042876 L NO 20042876L NO 20042876 A NO20042876 A NO 20042876A NO 20042876 A NO20042876 A NO 20042876A NO 20042876 L NO20042876 L NO 20042876L
Authority
NO
Norway
Prior art keywords
regeneration
pharmaceutical composition
cirrhotic liver
cirrhotic
liver
Prior art date
Application number
NO20042876A
Other languages
English (en)
Norwegian (no)
Inventor
Sang Geon Kim
Keon Wook Kang
Yoon Gyoon Kim
Min Kyung Cho
Original Assignee
Sang Geon Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sang Geon Kim filed Critical Sang Geon Kim
Publication of NO20042876L publication Critical patent/NO20042876L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20042876A 2002-02-09 2004-07-07 Farmasoytisk blanding for regenerering av cirrhotisk lever NO20042876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020020007678A KR20030067935A (ko) 2002-02-09 2002-02-09 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
PCT/KR2003/000278 WO2003066058A1 (en) 2002-02-09 2003-02-08 Pharmaceutical composition for regeneration of cirrhotic liver

Publications (1)

Publication Number Publication Date
NO20042876L true NO20042876L (no) 2004-09-01

Family

ID=27725720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042876A NO20042876L (no) 2002-02-09 2004-07-07 Farmasoytisk blanding for regenerering av cirrhotisk lever

Country Status (15)

Country Link
US (2) US20030171382A1 (pl)
EP (1) EP1471914A4 (pl)
JP (1) JP2005519926A (pl)
KR (1) KR20030067935A (pl)
CN (1) CN1278687C (pl)
AU (1) AU2003206245B2 (pl)
BR (1) BR0306923A (pl)
CA (1) CA2473202C (pl)
MX (1) MXPA04007675A (pl)
NO (1) NO20042876L (pl)
PL (1) PL371245A1 (pl)
RU (1) RU2291696C2 (pl)
TW (1) TWI248931B (pl)
WO (1) WO2003066058A1 (pl)
ZA (1) ZA200406059B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
KR100604261B1 (ko) * 2004-10-11 2006-07-28 재단법인서울대학교산학협력재단 신규4,5,6,7-테트라히드로-[1,2]디티올로[4,3-ｃ]피리딘-3-티온계 화합물
KR20060031956A (ko) * 2004-10-11 2006-04-14 재단법인서울대학교산학협력재단 ｐ90 리보솜 Ｓ6 키나제 1 (ＲＳＫ1)의 직접적인 키나제활성증진을 통한 간섬유화와 간경변증 예방 및 치료용약학조성물
WO2007131973A2 (en) 2006-05-11 2007-11-22 Prendergast Patrick T Compositions and methods for modulating the immune system
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
KR101057485B1 (ko) * 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
EP2346519B1 (en) 2008-10-02 2015-12-02 George Zabrecky Methods and formulations for treating chronic liver disease
EP2674159B1 (de) 2012-06-15 2016-04-27 Phrontier S.A.R.L. Pharmazeutische Zusammensetzung für die Leber-Regeneration
BR112018004518A2 (pt) 2015-09-08 2019-03-19 OP2 Drugs compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais
WO2017042267A1 (en) * 2015-09-08 2017-03-16 Orphan Partners 2 Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
JP6994240B2 (ja) * 2015-12-07 2022-02-04 国立大学法人京都大学 Ｐｄ－１シグナル阻害剤の併用療法
CA3055122A1 (en) 2017-03-07 2018-09-13 OP2 Drugs Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794873A (fr) * 1972-02-02 1973-08-01 Rhone Poulenc Sa Nouvelles sulfones a enchainement dimethyl-1,6 hexadien-1,5 ylene
DE2505869C3 (de) * 1975-02-12 1978-05-18 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von symmetrischen Carotinoiden
JPS54160740A (en) * 1978-06-09 1979-12-19 Takeda Chem Ind Ltd Anti-fibrotic agent
US4883887A (en) * 1987-07-09 1989-11-28 Hoffmann-La Roche Inc. Sulfone polyene intermediates
US6517824B1 (en) * 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
KR0138005B1 (ko) * 1993-10-21 1998-05-15 김낙두 신규의 화학적 보호제(chemopreventive agent)및 그의 제조방법
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
KR100261139B1 (ko) * 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AU6462500A (en) * 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
US6242478B1 (en) * 1999-12-10 2001-06-05 Wake Forest University Five member ring sulfenate esters and thiosulfinate esters
KR100377789B1 (ko) * 2000-03-02 2003-03-26 김상건 간섬유화 및 간경화 치료 및 예방용 의약 조성물
US7078045B2 (en) * 2000-03-02 2006-07-18 Sang-Geon Kim Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
CN1218698C (zh) * 2000-03-02 2005-09-14 金相建 用于治疗和预防肝纤维化和肝硬化的药物组合物
EP1292309A4 (en) * 2000-04-07 2004-08-11 Sang Geon Kim PROPHYLACTIC AND THERAPEUTIC USE OF OLTIPRAZ AS AN AGENT AGAINST FIBROSIS AND CIRRUSH OF THE LIVER AND PHARMACEUTICAL COMPOSITION CONTAINING OLTIPRAZ
KR100604261B1 (ko) * 2004-10-11 2006-07-28 재단법인서울대학교산학협력재단 신규4,5,6,7-테트라히드로-[1,2]디티올로[4,3-ｃ]피리딘-3-티온계 화합물

Also Published As

Publication number Publication date
JP2005519926A (ja) 2005-07-07
TWI248931B (en) 2006-02-11
CA2473202A1 (en) 2003-08-14
ZA200406059B (en) 2005-06-21
MXPA04007675A (es) 2004-11-10
RU2291696C2 (ru) 2007-01-20
WO2003066058A1 (en) 2003-08-14
TW200305570A (en) 2003-11-01
PL371245A1 (pl) 2005-06-13
KR20030067935A (ko) 2003-08-19
AU2003206245A1 (en) 2003-09-02
CA2473202C (en) 2007-11-13
CN1278687C (zh) 2006-10-11
US20030171382A1 (en) 2003-09-11
EP1471914A4 (en) 2007-08-08
RU2004127128A (ru) 2005-04-20
AU2003206245B2 (en) 2006-07-20
BR0306923A (pt) 2004-12-28
US20060063781A1 (en) 2006-03-23
CN1625399A (zh) 2005-06-08
EP1471914A1 (en) 2004-11-03

Similar Documents

Publication Publication Date Title
NO20043722L (no) Farmasoytiske blandinger for hepatitt C-virus-proteaseinhibitorer
ATE555809T1 (de) Pharmezeutische anti-tnf-alpha antikörper formulierung
EP1603593A4 (en) PHARMACEUTICAL COMPOSITION
EP1578940A4 (en) METHOD AND COMPOSITIONS FOR DYSPLASED DIAGNOSIS
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
FI20011478L (fi) Farmaseuttinen koostumus
EP1425019A4 (en) PHARMACEUTICAL COMPOSITION
DK1587478T3 (da) Farmaceutisk sammensætning
SK4326U (sk) Farmaceutická kompozícia s predĺženým uvoľňovaním
PL375978A1 (pl) Preparaty zawierające związek indolinonowy
NO20042876L (no) Farmasoytisk blanding for regenerering av cirrhotisk lever
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
ATE414705T1 (de) Entzündungshemmende di- und trifluortriazolopyridin-verbindungen
NO20055185D0 (no) Farmasoytiske sammensetninger omfattende atorvastatin fremstilt uten granulering
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
NO20040253L (no) Fremgangsmater for behandling av leverfibroser
FI20022128L (fi) Farmaseuttinen koostumus
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
ATE448780T1 (de) Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
IS7715A (is) Nýjar lyfjasamsetningar úr módafíníl
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK1467750T3 (da) Orodispergerbar farmaceutisk sammensætning omfattende perindopril
NO20031650L (no) Nye legemidler for leversykdommer
IS7958A (is) Aðferð til að framleiða metýl 2-dífenýlmetýlsúlfínýlasetat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application